1

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

jmzucpfgui58gb
Background: Pediatric gastroenteropancreatic neuroendocrine tumors are exceedingly rare. resulting in most pediatric treatment recommendations being based on data derived from adults. Trametinib is a kinase inhibitor that targets MEK1/2 and has been employed in the treatment of cancers harboring mutations in the Ras pathway. Methods: We utilized an established human pediatric gastroen... https://www.deliandiver.com/product-category/frother/
Report this page

Comments

    HTML is allowed

Who Upvoted this Story